inShare SeraCare Launches Circulating Tumor DNA Reference Materials for NGS and Digital PCR-based Oncology Assays

March 7, 2016

MILFORD, MA - Mar 7, 2016 - SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers, today announces the launch of two new circulating tumor DNA (ctDNA)  products at the 2016 Molecular Medicine Tri-Conference in San Francisco. The Seraseq™ Circulating Tumor DNA-I Reference Material and the Seraseq™ Circulating Tumor DNA-I Mutation Mix Kit are designed to assist both oncology assay developers and clinical laboratories in better characterizing the performance and robustness of their ctDNA assays and to monitor the performance across each run.  There is currently significant interest in ctDNA for the non-invasive monitoring of tumor dynamics and residual disease after initial therapy. However, the current lack of ‘ground truth’ reference materials useful for analytical validation and performance monitoring are urgently needed to advance the clinical implementation of these assays.